Structure

InChI Key MYSWGUAQZAJSOK-UHFFFAOYSA-N
Smile O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
InChI
InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)

Physicochemical Descriptors

Property Name Value
Molecular Formula C17H18FN3O3
Molecular Weight 331.35
AlogP 1.58
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 3.0
Polar Surface Area 74.57
Molecular species ZWITTERION
Aromatic Rings 2.0
Heavy Atoms 24.0

Experimental and Estimated Properties

Property Name Value Unit Method
log P (octanol-water) 0.28 - EXP
pKa Dissociation Constant 6.09 - EXP
Henry's Law Constant 5.09E-19 atm-m3/mole EST
Atmospheric OH Rate Constant 3.13E-10 cm3/molecule-sec EST
Water Solubility 3.00E+04 mg/L EXP
Vapor Pressure 1.65E-12 mm Hg EST

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Bacterial DNA gyrase inhibitor FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Prostatitis 4 D011472 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Sepsis 3 D018805 ClinicalTrials
Liver Abscess 3 D008100 ClinicalTrials
Fever 3 D005334 ClinicalTrials
Peritonitis 3 D010538 ClinicalTrials
Pulmonary Disease, Chronic Obstructive 3 D029424 ClinicalTrials
Digestive System Diseases 3 D004066 ClinicalTrials
Diarrhea 3 D003967 ClinicalTrials
Bronchiectasis 3 D001987 ClinicalTrials
Communicable Diseases 3 D003141 ClinicalTrials
Otitis Media 3 D010033 ClinicalTrials
Abscess 3 D000038 ClinicalTrials
Urolithiasis 3 D052878 ClinicalTrials
Pneumonia 3 D011014 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 3 D064129 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Neutropenia 3 D009503 ClinicalTrials
Cystic Fibrosis 2 D003550 ClinicalTrials
Crohn Disease 2 D003424 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 2 D015451 ClinicalTrials
Anthrax 2 D000881 ClinicalTrials
Amyotrophic Lateral Sclerosis 2 D000690 ClinicalTrials
Cataract 2 D002386 ClinicalTrials
Plague 2 D010930 ClinicalTrials
Diabetic Foot 1 D017719 ClinicalTrials
Lymphoma 1 D008223 ClinicalTrials
Leukemia, Myeloid, Acute 1 D015470 ClinicalTrials
Hepatitis C 1 D006526 ClinicalTrials
Periapical Periodontitis 1 D010485 ClinicalTrials
Escherichia coli Infections 1 D004927 ClinicalTrials
Hearing Loss 1 D034381 ClinicalTrials
Lung Diseases 1 D008171 ClinicalTrials
Carcinoma, Pancreatic Ductal 1 D021441 ClinicalTrials
Pseudomonas Infections 1 D011552 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials
Purpura, Thrombocytopenic, Idiopathic 1 D016553 ClinicalTrials
Hepatitis, Alcoholic 0 D006519 ClinicalTrials
Osteomyelitis 0 D010019 ClinicalTrials
Liver Cirrhosis, Alcoholic 0 D008104 ClinicalTrials
Rhinoscleroma 0 D012226 ClinicalTrials

Related Entries

MCS

Scaffolds

UNKNOWN
Mixture
Mixture

Side Effects from Label

Side effects Relative Frequency (%) Labels
Infections and infestations Pneumonia klebsiella 40.0
General disorders and administration site conditions Discomfort 9.7
General disorders and administration site conditions Discomfort
Gastrointestinal disorders Nausea 5.2
Gastrointestinal disorders Dysgeusia 5.0
Gastrointestinal disorders Nausea 4.0
Nervous system disorders Headache 3.0
Gastrointestinal disorders Nausea 3.0
Infections and infestations Fungal infection 2.6
Infections and infestations Nasopharyngitis 2.6
Gastrointestinal disorders Nausea 2.5
Nervous system disorders Headache 2.4
Gastrointestinal disorders Diarrhoea 2.3
Gastrointestinal disorders Diarrhoea 2.0
Cardiac disorders Dizziness 2.0
Nervous system disorders Headache 2.0
Renal and urinary disorders Micturition urgency 2.0
Renal and urinary disorders Pollakiuria 2.0
General disorders and administration site conditions Sensation of foreign body 2.0
Infections and infestations Vaginal infection 2.0
Vaginal inflammation 2.0
Gastrointestinal disorders Vomiting 2.0
Infections and infestations Vulvovaginal candidiasis 2.0
Infections and infestations Vulvovaginal mycotic infection 2.0
Skin and subcutaneous tissue disorders Pruritus
Skin and subcutaneous tissue disorders Dermatitis 1.8
Skin and subcutaneous tissue disorders Rash 1.8
General disorders and administration site conditions Sensation of foreign body 1.8
General disorders and administration site conditions Discomfort 1.7
Gastrointestinal disorders Diarrhoea 1.6
Infections and infestations Fungal infection 1.6
Nervous system disorders Headache 1.5
Skin and subcutaneous tissue disorders Erythema
Vascular disorders Hyperaemia
Investigations Liver function test abnormal 1.3
Gastrointestinal disorders Nausea 1.3
Skin and subcutaneous tissue disorders Erythema 1.2
Renal and urinary disorders Haematuria 1.2
Nervous system disorders Headache 1.2
Vascular disorders Hyperaemia 1.2
Skin and subcutaneous tissue disorders Pruritus 1.2
Nervous system disorders Agitation 1.1
Skin and subcutaneous tissue disorders Dermatitis 1.1
Skin and subcutaneous tissue disorders Pruritus 1.1
Skin and subcutaneous tissue disorders Rash 1.1
Skin and subcutaneous tissue disorders Dermatitis 1.0
Gastrointestinal disorders Diarrhoea 1.0
Cardiac disorders Dizziness 1.0
Gastrointestinal disorders Dyspepsia 1.0
Nervous system disorders Headache 1.0
General disorders and administration site conditions Injection site pain 1.0
Skin and subcutaneous tissue disorders Rash 1.0
Gastrointestinal disorders Vomiting 1.0
Infections and infestations Vulvovaginal candidiasis 1.0
Infections and infestations Vulvovaginal mycotic infection 1.0
Reproductive system and breast disorders Vulvovaginal pruritus 1.0
Blood and lymphatic system disorders Eosinophilia 0.6
Blood and lymphatic system disorders Leukopenia 0.4
Blood and lymphatic system disorders Pancytopenia 0.1

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Nervous system disorders
12.83
General disorders and administration site conditions
11.12
Musculoskeletal and connective tissue disorders
10.39
Immune system disorders
9.42
Skin and subcutaneous tissue disorders
8.14
Gastrointestinal disorders
6.86
Psychiatric disorders
6.8
Injury, poisoning and procedural complications
6.01
Vascular disorders
4.38
Cardiac disorders
3.71
Infections and infestations
3.28
Respiratory, thoracic and mediastinal disorders
3.04
Investigations
2.26
Renal and urinary disorders
2.23

Cross References

Resources Reference
CAS NUMBER 85721-33-1
ChEBI 100241
ChEMBL CHEMBL8
DrugBank DB00537
DrugCentral 659
EPA CompTox DTXSID8022824
FDA SRS 5E8K9I0O4U
Human Metabolome Database HMDB0014677
Guide to Pharmacology 10902
KEGG C05349
PDB CPF
PharmGKB PA449009
PubChem 2764
SureChEMBL SCHEMBL2900
ZINC ZINC000000020220